<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03639740</url>
  </required_header>
  <id_info>
    <org_study_id>TRACE</org_study_id>
    <secondary_id>2017-004037-93</secondary_id>
    <nct_id>NCT03639740</nct_id>
  </id_info>
  <brief_title>Treat-to-target With Secukinumab in Axial Spondyloarthritis</brief_title>
  <acronym>TRACE</acronym>
  <official_title>TReat-to-tArget (T2T) With seCukinumab in Axial Spondyloarthritis. IdEntification of MRI and Biochemical Biomarkers for Disease Activity, Treatment Response and Structural Damage Progression (the TRACE Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Professor Mikkel Østergaard</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Healthcare A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study of axSpA and AS receiving Secukinumab in a treat-to-target strategy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Comparison of reductions in MRI inflammation in the sacroiliac joints and spine from week 16&#xD;
      to 24 in patients who at week 16 are in ASDAS remission (i.e. continue sc. secukinumab 150 mg&#xD;
      monthly) vs. not in ASDAS remission (i.e. increase sc. secukinumab 300 mg monthly). ASDAS&#xD;
      remission is defined as ASDAS inactive disease i.e. ASDAS&lt;1.3.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Anticipated">January 15, 2019</start_date>
  <completion_date type="Anticipated">February 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Dose will be increased or maintained after predetermined intervals depending on remission</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with a positive change in MRI-inflammation</measure>
    <time_frame>Comparison of week 16 and 24</time_frame>
    <description>Assessed with the sum of SPARCC MRI SIJ and spine inflammation indices</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients in remission vs patients not in ASDAS (Ankylosing Spondylitis Disease Activity Score) remission.</measure>
    <time_frame>Comparison of week 16 and 24</time_frame>
    <description>as measured by remission (&lt;1.3) / not in ASDAS remission (&gt;1.3)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in ASDAS score (i.e. Ankylosing Spondylitis Disease Activity Score (ASDAS 0.6-7.0))</measure>
    <time_frame>Evaluated from week 0 to 16 and from week 16 to 24</time_frame>
    <description>as measured by changes in ASDAS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in MRI inflammation scores from week 0 to 16 and week 16 to 24, respectively.</measure>
    <time_frame>Week 0 to 16 and week 16 to 24</time_frame>
    <description>as measured by the SPARCC MRI SIJ and Spine Inflammation indices and the Canada-Denmark MRI system for a positive change in MRI inflammation in the spine as assessed with the Canada-Denmark MRI system for assessment of inflammation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in scores/anatomical location of MRI lesions in the spine</measure>
    <time_frame>week 16</time_frame>
    <description>as measured by the Canada-Denmark MRI system for assessment of inflammation, fat metaplasia, erosion, and new bone formation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in scores/anatomical location of MRI lesions in the SIJs</measure>
    <time_frame>week 16</time_frame>
    <description>as measured by the SPARCC MRI SIJ Inflammation Index and SPARCC SIJ Structural Score (SSS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRI inflammation</measure>
    <time_frame>week 16</time_frame>
    <description>as measured by the SPARCC (Spondyloarthritis Research Consortium of Canada) MRI sacroiliac joint and Spine Inflammation indices and the Canada-Denmark MRI system for assessment of inflammation assessed on cMRI (conventional MRI) i.e. on STIR (short tau inversion recovery) sequences on conventional and novel scan planes and on DWI (Diffusion-weighted imaging) sequences evaluated visually and based on regions of interest (ROIs).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">88</enrollment>
  <condition>Axial Spondyloarthritis</condition>
  <condition>Ankylosing Spondylitis</condition>
  <arm_group>
    <arm_group_label>Secukinumab 150 mg 300 mg or tumor necrosis factor inhibitor</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Secukinumab 150 mg sc. injection once a week for four weeks (induction phase) and thereafter once a month. If patients do not achieve ASDAS remission they get increased dosage of Secukinumab 300 mg sc. injection once a month. If still no ASDAS remission patients change to a TNF-inhibitor</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Secukinumab 150 milligram [Cosentyx]</intervention_name>
    <description>For intervention description: see arm/group description</description>
    <arm_group_label>Secukinumab 150 mg 300 mg or tumor necrosis factor inhibitor</arm_group_label>
    <other_name>Secukinumab 300 milligram [Cosentyx]</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of axial spondyloarthritis (axSpA) according to the ASAS (Assessment of&#xD;
             Spondyloarthritis International Society) criteria and/or ankylosing spondylitis (AS)&#xD;
             according to the modified New York criteria as judged by a spondyloarthritis (SpA)&#xD;
             rheumatologist (regarding imaging in the criteria, see below).&#xD;
&#xD;
          2. Active inflammation on MRI of the SIJs and/or spine as evaluated by a central SpA&#xD;
             imaging expert and/or radiographic modified New York criteria fulfilled as judged by a&#xD;
             central SpA imaging expert.&#xD;
&#xD;
          3. Active disease defined as ASDAS ≥ 2.1 (ASDAS high disease activity).&#xD;
&#xD;
          4. Total back pain as measured on a visual analogue scale (VAS) scale ≥ 4 0 mm (0-100 mm)&#xD;
             at baseline.&#xD;
&#xD;
          5. Clinical indication for a biologic drug as assessed by the treating physician.&#xD;
&#xD;
          6. Patients should have received at least 2 different NSAIDs at the highest recommended&#xD;
             dose for at least 2 weeks each with an inadequate response or failure to respond, or&#xD;
             less if therapy had to be reduced due to intolerance, toxicity or contraindications.&#xD;
&#xD;
          7. Patients on NSAIDs at inclusion should stay on a stable dose from at least 2 weeks&#xD;
             before the baseline MRI scans are performed and to the week 24 visit.&#xD;
&#xD;
          8. Patients on synthetic disease-modifying anti-rheumatic drugs (sDMARDs) at inclusion&#xD;
             should stay on a stable dose from at least 4 weeks before initiation of secukinumab to&#xD;
             the week 24 visit.&#xD;
&#xD;
          9. Patient must be able to understand and communicate with the investigator and comply&#xD;
             with the requirements of the study and must provide written, signed and dated informed&#xD;
             consent before any study assessment is performed.&#xD;
&#xD;
         10. Male or female patients at least 18 years and less than 70 years of age.&#xD;
&#xD;
         11. Sufficient contraception for women.&#xD;
&#xD;
         12. Age ≥18 to &lt;70 years.&#xD;
&#xD;
         13. Capable of giving informed consent.&#xD;
&#xD;
         14. Capable of complying with the examination programme of the protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Contraindications for secukinumab (described in protocol).&#xD;
&#xD;
          2. Contraindication for TNF inhibitor (described in protocol).&#xD;
&#xD;
          3. Contraindication for MRI (described in protocol).&#xD;
&#xD;
          4. Previous exposure to secukinumab or other biologic drug directly targeting&#xD;
             interleukin-17 or interleukin-17 receptor.&#xD;
&#xD;
          5. Previous exposure to TNF inhibitor or drug targeting TNF.&#xD;
&#xD;
          6. Previous exposure to other types of biological disease-modifying anti-rheumatic drugs&#xD;
             (bDMARDs) than TNF inhibitor.&#xD;
&#xD;
          7. Patients taking high-potency opioid analgesics (e.g. methadone, hydromorphone,&#xD;
             morphine)&#xD;
&#xD;
          8. Any change in the dose of oral corticosteroids in the last 8 weeks prior to the&#xD;
             baseline visit or use of i.v. intramuscular or intra-articular corticosteroid during&#xD;
             the last 8 weeks prior to the enrollment visit.&#xD;
&#xD;
          9. Use of any investigational drug and/or devices within 4 weeks before randomization or&#xD;
             a period of 5 half-lives of the investigational drug, whichever is longer.&#xD;
&#xD;
         10. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a&#xD;
             female after conception and until the termination of gestation, confirmed by a&#xD;
             positive human chorionic gonadotropin (hCG) laboratory test.&#xD;
&#xD;
         11. Women of child-bearing potential, defined as all women physiologically capable of&#xD;
             becoming pregnant, unless they are using effective methods of contraception during the&#xD;
             entire study or longer if required by locally approved prescribing information (e.g.&#xD;
             20 weeks in EU).&#xD;
&#xD;
         12. Known recent drug or alcohol abuse.&#xD;
&#xD;
         13. Incapable of complying with the examination programme for physical or mental reasons.&#xD;
&#xD;
         14. Failure to provide written consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mikkel Østergaard, DMSc PhD MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Susanne J Pedersen, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mikkel Østergaard, DMSc PhD MD</last_name>
    <phone>+45 38633015</phone>
    <email>mo@dadlnet.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sengül Seven, MD</last_name>
    <phone>+45 3863 3014</phone>
    <email>senguel.seven@regionh.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Reumatologisk Afdeling, Aarhus Universitetshospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Anne G Loft, MS DMSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Videncenter for Reumatologi og Rygsygdomme, Rigshospitalet - Frederiksberg</name>
      <address>
        <city>Frederiksberg</city>
        <zip>2000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Bente Jensen, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Videncenter for Reumatologi og Rygsygdomme, Rigshospitalet Glostrup</name>
      <address>
        <city>Glostrup</city>
        <zip>2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mikkel Østergaard, MD PhD DMSc</last_name>
    </contact>
    <investigator>
      <last_name>Mikkel Østergaard, MD PhD DMSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Susanne J Pedersen, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sengül Seven, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Inge J Sørensen, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kong Christian X´s Gigthospital</name>
      <address>
        <city>Gråsten</city>
        <zip>6300</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Oliver Hendricks, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Videncenter for Reumatologi og Rygsygdomme, Rigshospitalet - Gentofte</name>
      <address>
        <city>Hellerup</city>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ole R Madsen, MD PhD DMSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Videncenter for Reumatologi og Rygsygdomme, Rigshospitalet - Nordsjællands Hospital Hillerød</name>
      <address>
        <city>Hillerød</city>
        <zip>3400</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jesper Nørregaard, MD DMSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Reumatologisk Afdeling, Regionshospitalet Nordjylland, Hjørring</name>
      <address>
        <city>Hjørring</city>
        <zip>9800</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Marcin Kowalski, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Reumatologisk afdeling, Sjællands Universitetshospital, Køge</name>
      <address>
        <city>Køge</city>
        <zip>4600</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Bo Ejbjerg, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Reumatologisk Afdeling, Odense Universitetshospital</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Hans C Horn, consultant</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Reumatologisk Afdeling, Regionshospitalet Silkeborg</name>
      <address>
        <city>Silkeborg</city>
        <zip>8600</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Rene Østgaard, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>August 17, 2018</study_first_submitted>
  <study_first_submitted_qc>August 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 21, 2018</study_first_posted>
  <last_update_submitted>January 2, 2019</last_update_submitted>
  <last_update_submitted_qc>January 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Professor Mikkel Østergaard</investigator_full_name>
    <investigator_title>Professor, DMSc, PhD, MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spondylitis</mesh_term>
    <mesh_term>Spondylitis, Ankylosing</mesh_term>
    <mesh_term>Spondylarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

